331 related articles for article (PubMed ID: 17437889)
1. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Patereli A; Stratigos A; Katsambas A
J Am Acad Dermatol; 2007 May; 56(5):815-24. PubMed ID: 17437889
[TBL] [Abstract][Full Text] [Related]
2. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
3. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
4. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical evaluation of p16INK4A, E-cadherin, and cyclin D1 expression in melanoma and Spitz tumors.
George E; Polissar NL; Wick M
Am J Clin Pathol; 2010 Mar; 133(3):370-9. PubMed ID: 20154275
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.
Mason A; Wititsuwannakul J; Klump VR; Lott J; Lazova R
J Cutan Pathol; 2012 Dec; 39(12):1062-74. PubMed ID: 23005921
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
9. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
10. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study.
Garrido-Ruiz MC; Requena L; Ortiz P; Pérez-Gómez B; Alonso SR; Peralto JL
Mod Pathol; 2010 Sep; 23(9):1215-24. PubMed ID: 20543820
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
[TBL] [Abstract][Full Text] [Related]
13. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma.
Hilliard NJ; Krahl D; Sellheyer K
J Cutan Pathol; 2009 Jul; 36(7):753-9. PubMed ID: 19519606
[TBL] [Abstract][Full Text] [Related]
14. P21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters.
Poyraz A; Akyürek N; Gönül II; Erdem O
J Exp Clin Cancer Res; 2004 Dec; 23(4):625-31. PubMed ID: 15743033
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion.
Takata M; Lin J; Takayanagi S; Suzuki T; Ansai S; Kimura T; Cerroni L; Saida T
Br J Dermatol; 2007 Jun; 156(6):1287-94. PubMed ID: 17535228
[TBL] [Abstract][Full Text] [Related]
16. Allelic imbalance in the diagnosis of benign, atypical and malignant Spitz tumours.
van Dijk MC; Rombout PD; Mooi WJ; van de Molengraft FJ; van Krieken JH; Ruiter DJ; Ligtenberg MJ
J Pathol; 2002 Jun; 197(2):170-8. PubMed ID: 12015740
[TBL] [Abstract][Full Text] [Related]
17. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
18. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma.
Flørenes VA; Faye RS; Maelandsmo GM; Nesland JM; Holm R
Clin Cancer Res; 2000 Sep; 6(9):3614-20. PubMed ID: 10999753
[TBL] [Abstract][Full Text] [Related]
19. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
[TBL] [Abstract][Full Text] [Related]
20. Patient age in Spitz nevus and malignant melanoma: implication of Bayes rule for differential diagnosis.
Vollmer RT
Am J Clin Pathol; 2004 Jun; 121(6):872-7. PubMed ID: 15198360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
